Gouric Tablets 40Mg
Brand : pharmevo private limited.
Requires Prescription (YES/NO)
How it works
Febuxostat is a potent, non-purine, selective inhibitor of xanthine oxidase (XO) that achieves its therapeutic effect of decreasing serum uric acid by selectively inhibiting xanthine oxidase. Uric acid is the end product of purine metabolism and is generated in the cascade of hypoxanthine ! xanthine ! uric acid. Both steps in the transformation are catalyzed by xanthine oxidase.
USAGE AND SAFETY
Common : Headache, diarrhea, nausea, rash and LFT abnormalities.Uncommon : Blood amylase increase, platelet count decrease, blood creatinine increase, hemoglobin decrease, blood urea increase , LDH increase, triglycerides increase, dizziness, paraesthesia, somnolence, altered taste, abdominal pain, gastro-oesophageal reflux disease, vomiting, dry mouth, dyspepsia, constipation, frequent stools, flatulence, gastrointestinal discomfort, nephrolithiasis, hematuria, pollakiuria, dermatitis, urticaria, pruritus, arthralgia, arthritis, myalgia, muscle cramp, musculoskeletal pain, weight increase, increased appetite, hypertension, flushing, hot flush, fatigue, edema, influenza like symptoms and libido decreased. Rare : Palpitations, renal insufficiency, asthenia, thirst, nervousness and insomnia.
Naproxen and other inhibitors of glucuronidation , NSAIDs and probenecid , UGT enzymes
Febuxostat is indicated for the chronic management of hyperuricemia in patients with gout.
When not to Use
Febuxostat is contraindicated in patients with: - Hypersensitivity to the active substance or to any of the excipients of the product. - Being treated with azathioprine, mercaptopurine or theophylline. - Asymptomatic hyperuricemia.
Treatment with febuxostat in patients with ischemic heart disease or congestive heart failure is not recommended.
After initiation of febuxostat, an increase in gout flares is frequently observed. This increase is due to reduction in serum uric acid levels resulting in mobilization of urate from tissue deposits. In order to prevent gout flares when febuxostat is initiated, concurrent prophylactic treatment with an NSAID or colchicine is recommended.
As with other urate lowering medicinal products, in patients in whom the rate of urate formation is greatly increased (e.g. malignant disease and its treatment, Lesch-Nyhan syndrome) the absolute concentration of xanthine in urine could, in rare cases, rise sufficiently to allow deposition in the urinary tract. As there has been no experience with febuxostat, its use in these populations is not recommended.
Laboratory assessment of liver function is recommended at, for example 2 and 4 months following initiation of febuxostat and periodically thereafter.
Always consult your physician before using any medicine.
Store this medicine at room temperature, away from direct light and heat.